Chronic high-dose dimenhydrinate use contributing to early multifactorial cognitive impairment.
Nicholas FabianoSaumil DholakiaLisa A S WalkerAndrew L SmithPublished in: BMJ case reports (2024)
Dimenhydrinate is an over-the-counter antihistaminergic medication with anticholinergic properties used to treat nausea or motion sickness worldwide. There is a well-established correlation between the use of anticholinergic medications and dementia, however, it is unclear if a causal role exists. We report a case of minor neurocognitive disorder in a woman in her 40s with several years of high-dose daily dimenhydrinate abuse who subsequently developed significant delusional beliefs. Her clinical presentation was confounded by numerous other factors that could have impacted her cognition, such as a longstanding presumed learning disability, ankylosing spondylitis with adalimumab treatment, extensive cannabis use or potential development of a primary psychotic disorder. Her workup was within normal limits, and she has not responded to first-line antipsychotic medications to date. This case report adds to the growing evidence supporting concerns about potentially irreversible cognitive deficits in chronic misuse of anticholinergic agents, an association previously observed only in the elderly population.
Keyphrases
- high dose
- ankylosing spondylitis
- cognitive impairment
- case report
- rheumatoid arthritis
- low dose
- stem cell transplantation
- mild cognitive impairment
- bipolar disorder
- disease activity
- multiple sclerosis
- chronic pain
- healthcare
- physical activity
- juvenile idiopathic arthritis
- middle aged
- emergency department
- human health
- adverse drug
- systemic lupus erythematosus
- high resolution
- drug induced
- community dwelling
- high speed
- climate change